Viswanathan Natarajan Selected Research

Viswanathan Natarajan Research Topics

Disease

29	Lung Injury 12/2022 - 04/2003
25	Inflammation (Inflammations) 01/2024 - 08/2002
20	Hyperoxia 01/2022 - 01/2003
17	Pneumonia (Pneumonitis) 03/2022 - 04/2009
16	Acute Lung Injury 01/2022 - 09/2005
13	Pulmonary Fibrosis (Fibrosing Alveolitis) 09/2021 - 08/2012
13	Fibrosis (Cirrhosis) 08/2020 - 01/2013
11	Infections 03/2021 - 07/2003
10	Asthma (Bronchial Asthma) 01/2024 - 04/2007
10	Neoplasms (Cancer) 12/2019 - 02/2003
8	Hypoxia (Hypoxemia) 11/2022 - 12/2010
8	Bronchopulmonary Dysplasia 01/2022 - 10/2013
8	Sepsis (Septicemia) 09/2021 - 04/2009
7	Lung Diseases (Lung Disease) 03/2020 - 11/2006
6	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 06/2024 - 12/2003
6	Lung Neoplasms (Lung Cancer) 09/2021 - 01/2008
6	Idiopathic Pulmonary Fibrosis 03/2020 - 04/2013
4	Pulmonary Arterial Hypertension 11/2022 - 10/2009
3	Critical Illness (Critically Ill) 06/2024 - 01/2013
3	Airway Remodeling 03/2024 - 01/2020
3	Pulmonary Hypertension 11/2022 - 11/2014
3	Vascular Remodeling 11/2022 - 12/2017
3	Chronic Obstructive Pulmonary Disease (COPD) 03/2022 - 09/2009
3	Pulmonary Edema 01/2022 - 12/2003
3	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 01/2016
3	Ventilator-Induced Lung Injury 01/2022 - 12/2015
3	Pathologic Processes 01/2020 - 05/2009
3	Prostatic Neoplasms (Prostate Cancer) 06/2013 - 12/2010
3	Breast Neoplasms (Breast Cancer) 12/2010 - 10/2004
2	Retinoblastoma (Glioblastoma, Retinal) 08/2022 - 01/2017
2	Mitochondrial Diseases (Mitochondrial Disease) 03/2022 - 01/2022
2	COVID-19 01/2022 - 01/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2019
2	Respiratory Hypersensitivity 01/2020 - 11/2008
2	Necrosis 01/2019 - 01/2015
2	Cystic Fibrosis (Mucoviscidosis) 01/2018 - 09/2009
2	Respiratory Insufficiency (Respiratory Failure) 01/2018 - 04/2012

Drug/Important Bio-Agent (IBA)

26	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 03/2024 - 08/2002
21	Proteins (Proteins, Gene)FDA Link 11/2022 - 04/2003
19	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 01/2003
15	sphingosine kinaseIBA 01/2024 - 08/2010
15	SphingolipidsIBA 01/2022 - 08/2002
13	lysophosphatidic acidIBA 09/2021 - 03/2009
12	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2022 - 01/2003
12	LipidsIBA 06/2020 - 05/2005
11	SphingosineIBA 01/2022 - 04/2009
11	CytokinesIBA 01/2022 - 09/2005
11	Small Interfering RNA (siRNA)IBA 01/2016 - 08/2007
10	EnzymesIBA 09/2021 - 05/2005
10	Bleomycin (Blenoxane)FDA LinkGeneric 08/2020 - 04/2013
9	Phosphotransferases (Kinase)IBA 01/2022 - 01/2003
8	Tyrosine (L-Tyrosine)FDA Link 05/2015 - 04/2003
7	Biomarkers (Surrogate Marker)IBA 01/2022 - 11/2005
7	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 01/2016 - 01/2003
6	AllergensIBA 01/2024 - 02/2006
6	Superoxides (Superoxide)IBA 11/2017 - 01/2003
5	CortactinIBA 01/2022 - 08/2007
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2006
5	Phosphates (Orthophosphate)IBA 09/2021 - 05/2009
5	Phospholipids (Phosphatides)FDA LinkGeneric 09/2021 - 05/2006
5	Sphingosine-1-Phosphate ReceptorsIBA 12/2019 - 10/2010
5	1-dodecylpyridoxal (PLD)IBA 01/2019 - 04/2003
5	CeramidesIBA 01/2018 - 05/2005
5	LyasesIBA 01/2017 - 10/2013
5	Lysophosphatidic Acid ReceptorsIBA 12/2013 - 11/2009
4	SmokeIBA 06/2024 - 01/2021
4	PF-543IBA 01/2024 - 01/2020
4	LipopolysaccharidesIBA 01/2022 - 05/2006
4	Extracellular Matrix ProteinsIBA 06/2020 - 12/2013
4	sphingosine 1-phosphate lyase (aldolase)IBA 01/2018 - 08/2011
4	Fingolimod Hydrochloride (FTY720)FDA Link 01/2016 - 06/2013
4	PaxillinIBA 12/2015 - 01/2008
3	LigandsIBA 12/2022 - 01/2021
3	Nicotinamide PhosphoribosyltransferaseIBA 01/2022 - 11/2005
3	Mitochondrial DNA (mtDNA)IBA 08/2020 - 01/2019
3	Peptides (Polypeptides)IBA 01/2020 - 08/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2019 - 05/2005
3	Phospholipase DIBA 01/2019 - 04/2003
3	Histones (Histone)IBA 01/2019 - 01/2012
3	NADP (NADPH)IBA 12/2017 - 01/2003
3	NADPH Oxidase 4IBA 11/2017 - 06/2011
3	Organophosphonates (Phosphonates)IBA 01/2016 - 07/2013
3	Particulate MatterIBA 04/2012 - 11/2008
2	GTP Phosphohydrolases (GTPases)IBA 12/2022 - 12/2009
2	Cardiolipins (Cardiolipin)IBA 03/2022 - 06/2014
2	Retinaldehyde (Retinal)IBA 01/2022 - 01/2016
2	NF-kappa B (NF-kB)IBA 01/2022 - 01/2005
2	Oxygen (Dioxygen)IBA 09/2021 - 01/2013
2	AsbestosIBA 08/2020 - 01/2020
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2020 - 01/2012
2	LysophospholipidsIBA 06/2020 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 09/2009
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2020 - 01/2015
2	Oxidants (Oxidizing Agents)IBA 01/2020 - 12/2005
2	Phosphatidic Acids (Phosphatidic Acid)IBA 01/2019 - 02/2015
2	indium-bleomycinIBA 01/2019 - 04/2013
2	Protein Kinase CIBA 01/2019 - 03/2011

Therapy/Procedure

12	Therapeutics 01/2022 - 05/2005
7	Mechanical Ventilators (Ventilator) 01/2022 - 04/2009
4	Artificial Respiration (Mechanical Ventilation) 12/2022 - 07/2013